Meanwhile, the combination of Bruton's tyrosine kinase inhibitor (BTKi) with anti‐CD20 therapy has been utilized in many B‐cell lymphomas [15, 16]. The gene discussed is BTK; the disease is B-cell non-Hodgkin lymphoma.